Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 3/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28165 | 0.82 | NAPRT (0.45) | NAPRTKDM4ENPC1ENPP2 | |
| SCHEMBL28695697 | 0.80 | DHODH (0.45) | NAPRTDHODHCYP11B2NPC1MAPT | |
| Water SCHEMBL29957279 | 0.80 | NAPRT (0.44) | NAPRTCYP11B2KDM4EENPP2 | |
| Water SCHEMBL343330 | 0.80 | NAPRT (0.44) | NAPRTCYP11B2KDM4EENPP2 | |
| Water SCHEMBL29956357 | 0.80 | NAPRT (0.44) | NAPRTCYP11B2KDM4EENPP2 | |
| SCHEMBL910658 | 0.77 | ENPP2 (0.50) | ENPP2MAPT | |
| SCHEMBL28857807 | 0.75 | KDM4E (0.45) | NAPRTDHODHCYP11B2MAOAMAOB | |
| SCHEMBL29216449 | 0.74 | KDM4E (0.46) | KDM4ENPC1MAPT | |
| SCHEMBL28676771 | 0.74 | ENPP2 (0.40) | KDM4EENPP2MAPT | |
| SCHEMBL29952228 | 0.73 | KDM4E (0.50) | KDM4ENPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062269-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062269-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | NAPRT 36/4885DHODH 1323/4885CYP11B2 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.